TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31023296

Group type: EXPERIMENTAL
Intervention: Testosterone therapy administered by injection every 4 weeks
Number of subjects: 15
Study: 31023377

Group type: EXPERIMENTAL
Intervention: Resistant hypertension
Number of subjects: 15656

Group type: COMPARATOR
Intervention: Controlled hypertension
Number of subjects: 15656

Group type: COMPARATOR
Intervention: Controlled resistant hypertension
Number of subjects: 15656
Study: 31023700

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg/day monotherapy
Number of subjects: 436
Study: 31024007

Group type: EXPERIMENTAL
Intervention: Transplantation of clinical-grade human neural stem cells (hNSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated SOD1 rats and those treated with HBSS)
Number of subjects: 0
Study: 31024276

Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity (FC) analysis in ASD males and females
Number of subjects: 120

Group type: COMPARATOR
Intervention: Resting-state functional connectivity (FC) analysis in control males and females
Number of subjects: 120
Study: 31024430

Group type: EXPERIMENTAL
Intervention: Consecutive Slides on Axial View
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transversal Diameter
Number of subjects: 0
Study: 31024436

Group type: EXPERIMENTAL
Intervention: Pre-injury comorbidities
Number of subjects: 0
Study: 31024734

Group type: EXPERIMENTAL
Intervention: HA + mannitol
Number of subjects: 22

Group type: COMPARATOR
Intervention: HA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 31024845

Group type: EXPERIMENTAL
Intervention: Radiation dose to reconstructed breast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no radiation dose specified)
Number of subjects: 0
Study: 31024978

Group type: EXPERIMENTAL
Intervention: Vaccination with HEV239 vaccine
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Natural infection with HEV
Number of subjects: 167

Group type: COMPARATOR
Intervention: Comparison of vaccinated vs naturally infected
Number of subjects: 167
Study: 31025045

Group type: EXPERIMENTAL
Intervention: Human gut microbiota transferred to germ-free NOD mice
Number of subjects: 5
Study: 31025952

Group type: EXPERIMENTAL
Intervention: N-PDT (Flexitheralight device)
Number of subjects: 42

Group type: COMPARATOR
Intervention: C-PDT (Aktilite CL 128 device)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: N-PDT
Number of subjects: 42
Study: 31025953

Group type: EXPERIMENTAL
Intervention: PDT using the Phosistos protocol (P-PDT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: PDT using the conventional protocol (C-PDT)
Number of subjects: 46
Study: 31026576

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1 therapy)
Number of subjects: 37
Study: 31026764

Group type: EXPERIMENTAL
Intervention: Improvement in patient quality of life over 24 months
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Improvement in family burden over 24 months
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Initial levels of positive symptoms
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association between quality of life and family burden
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association between family burden and quality of life
Number of subjects: 282
Study: 31027916

Group type: EXPERIMENTAL
Intervention: Abivertinib (50-350 mg twice daily or 300 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abivertinib
Number of subjects: 30
Study: 31028053

Group type: EXPERIMENTAL
Intervention: Family-administered FAM-CAM
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Family-administered Sour Seven questionnaire
Number of subjects: 21

Group type: COMPARATOR
Intervention: Trained research assistants using Confusion Assessment Method for the ICU 7
Number of subjects: 21
Study: 31028235

Group type: EXPERIMENTAL
Intervention: Neural respiratory drive (NRD) measured by change in parasternal muscle electromyogram (EMGpara)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120
Study: 31028290

Group type: EXPERIMENTAL
Intervention: Cortical thickness in individuals with ASD
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Cortical thickness in younger individuals with ASD
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Cortical thickness in individuals with lower full-scale intelligence (FIQ)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Cortical thickness related to clinical severity
Number of subjects: 491
Study: 31028495

Group type: EXPERIMENTAL
Intervention: EXAcerbations of COPD Tool (EXACT®) questionnaire, daily observations over a year.
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Markov models applied to the EXACT® item responses.
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IRT model with Markovian properties.
Number of subjects: 127
Study: 31028506

Group type: EXPERIMENTAL
Intervention: Scoring system based on features associated with survival (age, smoking, CA125, SCC, KPS, EGFR status)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Model validation of the scoring system
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of 176 patients
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Prospective validation in another 63 patients (NCT03363685)
Number of subjects: 176
Study: 31028664

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg QD
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ivosidenib (various doses from 100 mg BID to 1200 mg QD)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ivosidenib (various doses)
Number of subjects: 168
Study: 31028699

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline diet (BD)
Number of subjects: 17
Study: 31029086

Group type: EXPERIMENTAL
Intervention: HLA antigen bead assay reactivity profiles
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Classifier based on continuous data and multiparameter classification method
Number of subjects: 52
Study: 31030414

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg bid for 4 days, followed by apixaban 10 mg and clarithromycin 500 mg bid on day 8.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Apixaban 10 mg alone on day 1 and day 8.
Number of subjects: 19
Study: 31030528

Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 6466
Study: 31030969

Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Number of subjects: 177
Study: 31031089

Group type: EXPERIMENTAL
Intervention: iCAST Covered Stent
Number of subjects: 152
Study: 31031265

Group type: EXPERIMENTAL
Intervention: High-dose opioids (increased dose over the last 14 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High-dose opioids (no increase of dose over the last 14 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 63
Study: 31031906

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 61
Study: 31032113

Group type: EXPERIMENTAL
Intervention: Trypan blue capsule staining during phacoemulsification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phacoemulsification without trypan blue capsule staining (control)
Number of subjects: 0
Study: 31032258

Group type: EXPERIMENTAL
Intervention: Multi-ingredient supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 0
Study: 31033034

Group type: EXPERIMENTAL
Intervention: Dimethylfumarate monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fumaric acid ester mixture
Number of subjects: 0
Study: 31033050

Group type: EXPERIMENTAL
Intervention: Weaning from the incubator to the crib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (incubator care)
Number of subjects: 0
Study: 31033194

Group type: EXPERIMENTAL
Intervention: Anticoagulants stopped if d-dimer was negative
Number of subjects: 410

Group type: COMPARATOR
Intervention: Anticoagulants continued if d-dimer was positive
Number of subjects: 410
Study: 31033443

Group type: EXPERIMENTAL
Intervention: 10% Happier app
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Calm app
Number of subjects: 128

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 128
Study: 31033623

Group type: EXPERIMENTAL
Intervention: Isotope-labeled 3 mg aqueous zinc administered in the fasted state
Number of subjects: 40
Study: 31033629

Group type: EXPERIMENTAL
Intervention: Real-time adherence feedback
Number of subjects: 59
Study: 31034595

Group type: EXPERIMENTAL
Intervention: Patients with breast cancer receiving chemotherapy
Number of subjects: 376
Study: 31034642

Group type: EXPERIMENTAL
Intervention: Culturally targeted Hispanic Kidney Transplant Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for kidney transplant
Number of subjects: 0
Study: 31034676

Group type: EXPERIMENTAL
Intervention: Dementia Questionnaire (DQ) utilizing proxy-based assessments
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: SCAP cases inclusion
Number of subjects: 1260
Study: 31034999

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 31035265

Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Number of subjects: 14
Study: 31035291

Group type: EXPERIMENTAL
Intervention: Mavacamten 10 to 20 mg/d (cohort A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mavacamten 2 to 5 mg/d with β-blockers (cohort B)
Number of subjects: 21
Study: 31036012

Group type: EXPERIMENTAL
Intervention: Non-biologic disease-modifying antirheumatic drugs (non-bDMARDs)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Biologic disease-modifying antirheumatic drugs (biologic DMARDs)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Retired patients at baseline
Number of subjects: 210
Study: 31036014

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Monitoring of clinical and laboratory parameters
Number of subjects: 2

Group type: COMPARATOR
Intervention: Thick blood smear microscopy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Haematological evaluations
Number of subjects: 2
Study: 31036332

Group type: EXPERIMENTAL
Intervention: Increased frailty (measured by Clinical Frailty Scale)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Minor complications
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists score
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Overall hospitalization costs
Number of subjects: 321
Study: 31036762

Group type: EXPERIMENTAL
Intervention: Connections between face-processing network and medial temporal lobe memory system (including the hippocampus) and social processing system.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Face processing network interactions
Number of subjects: 50
Study: 31036770

Group type: EXPERIMENTAL
Intervention: Regorafenib 100 mg p.o. daily (continuous dosing)
Number of subjects: 25
Study: 31036879

Group type: EXPERIMENTAL
Intervention: Anti-GITR-based combination immunotherapy
Number of subjects: 0
Study: 31037275

Group type: EXPERIMENTAL
Intervention: 100% Tart Cherry Juice (TCJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31037293

Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE)
Number of subjects: 1000
Study: 31038467

Group type: EXPERIMENTAL
Intervention: Current patient monitoring systems
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Future patient monitoring systems
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Barriers to implementation of novel technology
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: User-derived findings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Digital health technology
Number of subjects: 15
Study: 31038469

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 10 mg on visit 1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 10 mg on visit 2
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 30 mg on visit 3
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 50 mg on visit 4
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Blood sample drawn on visit 5
Number of subjects: 7
Study: 31038781

Group type: EXPERIMENTAL
Intervention: Patients with LDL-C below the target of 70 mg/dL
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Patients with illiteracy
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Patients who believe cholesterol treatment should be terminated when cholesterol normalizes
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Physician perceptions about LDL-C goal for secondary prevention
Number of subjects: 1482
Study: 31039409

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT in first-HSCT patients (n=86)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT in patients who went directly to first HSCT upon remission (n=73)
Number of subjects: 101
Study: 31039789

Group type: EXPERIMENTAL
Intervention: Severity of insulin resistance (measured by HOMA-IR)
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of HOMA-IR
Number of subjects: 3128
Study: 31039807

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (weight-tiered: <75 kg: 10 mg/kg; 75-100 kg: 750 mg; >100 kg: 1000 mg) administered at Weeks 0, 2, 4, and every 4 weeks thereafter for 16 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 20
Study: 31040126

Group type: EXPERIMENTAL
Intervention: VEGF-A/ANG-2 neutralization
Number of subjects: 0
Study: 31040256

Group type: EXPERIMENTAL
Intervention: EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54-60 Gy/27-30 F/5.5-6 w)
Number of subjects: 10
Study: 31040791

Group type: EXPERIMENTAL
Intervention: -12° Head Down Tilt (HDT) for 21 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Horizontal position for 21 hours
Number of subjects: 11
Study: 31041522

Group type: EXPERIMENTAL
Intervention: Patella locking plate fixation
Number of subjects: 20
Study: 31042149

Group type: EXPERIMENTAL
Intervention: Text messaging, theory-driven newsletters, and behavioral coaching for changing sedentary behavior.
Number of subjects: 0
Study: 31042669

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously twice-daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 31042684

Group type: EXPERIMENTAL
Intervention: SpikeDeeptector algorithm
Number of subjects: 7
Study: 31042825

Group type: EXPERIMENTAL
Intervention: bb2121 CAR T-cell therapy
Number of subjects: 33
Study: 31043157

Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (WBVT) - 20 Hz, 2 mm amplitude, 3 bouts of 3 minutes, 4 days per week for 4 weeks.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (WBVT)
Number of subjects: 14
Study: 31043390

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D (1,000 IU/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (5,000 IU/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (without vitamin D)
Number of subjects: 3
Study: 31043539

Group type: EXPERIMENTAL
Intervention: DISH present
Number of subjects: 1784

Group type: COMPARATOR
Intervention: DISH absent
Number of subjects: 1784
Study: 31044001

Group type: EXPERIMENTAL
Intervention: Liver Qi Stagnation (LQS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Heart and Spleen Deficiency (HSD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Insular connectivity
Number of subjects: 44
Study: 31044307

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 55
Study: 31044328

Group type: EXPERIMENTAL
Intervention: Right coronary artery (RCA) motion analysis during selective coronary angiography
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Right coronary artery (RCA) maximum speed during selective coronary angiography
Number of subjects: 97
Study: 31044414

Group type: EXPERIMENTAL
Intervention: Preoperative anemia
Number of subjects: 851
Study: 31044728

Group type: EXPERIMENTAL
Intervention: Nonsupine positioning after pars plana vitrectomy with internal limiting membrane peeling and sulfur hexafluoride gas tamponade for 3 to 5 days.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Nonsupine positioning
Number of subjects: 203
Study: 31045222

Group type: EXPERIMENTAL
Intervention: Standard-dose intradermal influenza vaccine
Number of subjects: 158
Study: 31045797

Group type: EXPERIMENTAL
Intervention: Screening for hepatitis B virus (HBV) using HBsAg, anti-HBs, and anti-HBc tests after educational meetings, at the Outpatient Hepatology Department, and home visits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational meetings concerning viral hepatitis B.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up assessment of HBsAg-positive patients six months after screening.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection, and vaccination status.
Number of subjects: 0
Study: 31045955

Group type: EXPERIMENTAL
Intervention: Designated code team and hospital-wide code team activation system
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Preassigned roles for code team members
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Use of step stool and backboard during resuscitations
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Use of CPR feedback
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Audiovisual feedback device incorporated into the defibrillator
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Use of CPR coach
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multidisciplinary and simulation-based code team training
Number of subjects: 18
Study: 31046124

Group type: EXPERIMENTAL
Intervention: Total circulating cell-free DNA (cfDNA) levels above upper limit of normal (ULN)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Total circulating cell-free DNA (cfDNA) levels below upper limit of normal (ULN)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: cfDNA levels predicted by tumor burden and inflammatory response
Number of subjects: 493
Study: 31046586

Group type: EXPERIMENTAL
Intervention: Digital Memory Notebook (DMN) application intervention
Number of subjects: 3
Study: 31046714

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg q3w i.v. for 2 cycles)
Number of subjects: 30
Study: 31046720

Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP) treatment including individual counseling, tailored PA recommendation, written prescription, and structured follow-up for 6 months
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP) treatment
Number of subjects: 444
Study: 31046730

Group type: EXPERIMENTAL
Intervention: Novosyn® Quick
Number of subjects: 100
Study: 31046729

Group type: EXPERIMENTAL
Intervention: Thirdhand smoke (THS) exposure in homes of smokers who smoke indoors, have smoking bans, or have quit smoking.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secondhand smoke (SHS) exposure in homes of smokers who smoke indoors, have smoking bans, or have quit smoking.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical analyses of home dust samples for THS pollutants.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic medical record review of child respiratory illness.
Number of subjects: 0
Study: 31046743

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every third week in combination with entinostat 5 mg orally once weekly.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 29
Study: 31046764

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia (CAP)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cluster analysis of lipid profiles in CAP patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Specific lipid profiles in CAP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 30-day mortality in CAP clusters
Number of subjects: 52
Study: 31046839

Group type: EXPERIMENTAL
Intervention: Intratumoral treatment with BO-112
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intratumoral treatment with BO-112 plus systemic anti-CD137 and anti-PD-L1 mAbs
Number of subjects: 0
Study: 31047001

Group type: EXPERIMENTAL
Intervention: HDL apolipoproteomic score (pCAD)
Number of subjects: 943
Study: 31047111

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31047115

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) delivered by breath-actuated inhaler (BAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31047503

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 746

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 746
Study: 31047955

Group type: EXPERIMENTAL
Intervention: SGRQ CB definition
Number of subjects: 7557

Group type: COMPARATOR
Intervention: Classic CB definition
Number of subjects: 7557
Study: 31048098

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) - Epidiolex®
Number of subjects: 100
Study: 31048330

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg Q2W
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg Q2W, 240 mg Q2W, 360 mg once every 3 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg, 240 mg, 360 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 51
Study: 31048351

Group type: EXPERIMENTAL
Intervention: Cumulative effect of smoking on disease burden
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative effect of smoking on multimorbidity
Number of subjects: 0
Study: 31048587

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) prediction model
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 603

Group type: COMPARATOR
Intervention: Logistic Regression (LR) model
Number of subjects: 603